Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation.

about

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

P2860

Q55352057-B7CD55EE-9DF1-4484-A0D9-066D42D5BE16

P2860

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation.

Item

http://www.wikidata.org/entity/Q47113667

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Enhanced response of melanoma ...... biased IGF-1R down-regulation.

@en

Enhanced response of melanoma ...... biased IGF-1R down-regulation.

@nl

type

Item

label

Enhanced response of melanoma ...... biased IGF-1R down-regulation.

@en

Enhanced response of melanoma ...... biased IGF-1R down-regulation.

@nl

prefLabel

Enhanced response of melanoma ...... biased IGF-1R down-regulation.

@en

Enhanced response of melanoma ...... biased IGF-1R down-regulation.

@nl

P1476

Enhanced response of melanoma ...... biased IGF-1R down-regulation.

@en

P2093

Ada Girnita

http://www.w3.org/2001/XMLSchema#string

Anica Dricu

http://www.w3.org/2001/XMLSchema#string

Caitrin Crudden

http://www.w3.org/2001/XMLSchema#string

Claire Worrall

http://www.w3.org/2001/XMLSchema#string

Leonard Girnita

http://www.w3.org/2001/XMLSchema#string

Naida Suleymanova

http://www.w3.org/2001/XMLSchema#string

P2860

{beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase

Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Pathways and therapeutic targets in melanoma

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

Beta-arrestins and cell signaling

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.

P304

82256-82267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19286

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29137261

http://www.w3.org/2001/XMLSchema#string

P921

bias

P932

5669887

http://www.w3.org/2001/XMLSchema#string

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation.

about

P2860

P2860

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932